



Cite this: *Med. Chem. Commun.*, 2017, 8, 2164

## Correction: Development of highly active anti-*Pneumocystis* bisbenzamidines: insight into the influence of selected substituents on the *in vitro* activity

D. Maciejewska,<sup>\*a</sup> J. Żabiński,<sup>a</sup> M. Rezler,<sup>a</sup> P. Kaźmierczak,<sup>a</sup> M. S. Collins,<sup>bc</sup> L. Ficker<sup>bc</sup> and M. T. Cushion<sup>\*bc</sup>

DOI: 10.1039/c7md90042b

rsc.li/medchemcomm

Correction for 'Development of highly active anti-*Pneumocystis* bisbenzamidines: insight into the influence of selected substituents on the *in vitro* activity' by D. Maciejewska *et al.*, *Med. Chem. Commun.*, 2017, 8, 2003–2011.

The authors regret that on page 7 of their article the name for compound 13 contains an error. The correct name for 13 is: 1,5-bis(4-amidino-2-nitrophenoxy)-3-oxapentane dihydrochloride (with -2- instead of -3-nitrophenoxy).

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

<sup>a</sup> Department of Organic Chemistry, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1 Street, 02-097 Warsaw, Poland. E-mail: dmaciejewska@wum.edu.pl

<sup>b</sup> Division of Infectious Diseases, Department of Internal Medicine, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267, USA.  
E-mail: cushionmt@ucmail.uc.edu

<sup>c</sup> Cincinnati Veterans Affairs Medical Center, 3200 Vine Street, Cincinnati, OH 45220, USA